---
title: "Regeneron’s Pasatru wins FDA approval in ultra-rare ‘stone man disease’"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296501091.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-08-20T10:39:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296501091.md)
  - [en](https://longbridge.com/en/news/296501091.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296501091.md)
generator: "portal-rs"
---

# Regeneron’s Pasatru wins FDA approval in ultra-rare ‘stone man disease’

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296847570.md)
- [Does First-in-Class FOP Drug Approval Transform the Bull Case For Regeneron Pharmaceuticals (REGN)?](https://longbridge.com/en/news/296702017.md)
- [Regeneron podcast turns science into immersive experience](https://longbridge.com/en/news/296758441.md)
- [Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims](https://longbridge.com/en/news/296616209.md)
- [18:14 ETRegeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit](https://longbridge.com/en/news/297093753.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**